Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01417078 · ClinicalTrials.gov registry record · Phase 2

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

A Phase 2 study, sponsored by Acorda Therapeutics.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target

NCT01417078 is a Phase 2 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 31 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01417078, a Phase 2 study, has completed, sponsored by Acorda Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target

Study Summary

The purpose of this study is to determine the pharmacokinetics of Diazepam Nasal Spray following a single dose in epileptic patients experiencing a seizure episode.

Interventions

  • DRUG Diazepam

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2011-09
Est. Completion 2013-03
Phase Phase 2

Sponsor

Acorda Therapeutics

36 total trials

What the Registry Record Tells You About NCT01417078

The ClinicalTrials.gov registry entry for NCT01417078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Diazepam is the first listed.

NCT01417078 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01417078 about?

NCT01417078 is a clinical study titled "A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode". The purpose of this study is to determine the pharmacokinetics of Diazepam Nasal Spray following a single dose in epileptic patients experiencing a seizure episode.

What is the current status of trial NCT01417078?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-09. Estimated completion is 2013-03.

What interventions are being tested in trial NCT01417078?

The interventions under investigation include: Diazepam (DRUG).

Who is sponsoring clinical trial NCT01417078?

This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.